Abstract: A speaker device includes a frame, a vibration unit fixedly connected to the frame, a magnetic circuit unit having a magnetic gap, and a screen cloth. The vibration unit includes a diaphragm and a voice coil. The magnetic circuit unit includes a carrier, a first main magnet, an auxiliary magnet and a magnetic conductive plate. The magnetic conductive plate is fixed to the frame. The magnetic conductive plate includes a first central portion and a first edge portion; the auxiliary magnet is located at the first central portion. The first edge portion is provided with a through hole. The screen cloth is provided at a side of the carrier away from the diaphragm, and includes a second central portion and a second edge portion. The second edge portion is provided with a first groove recessed toward the magnetic conductive plate, corresponding to the through hole.

Abstract: The present disclosure relates to a fusion protein comprising an antigen-binding moiety that binds specifically to human PD-1 and an IL2 moiety, and methods of use thereof.

Abstract: The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided.

Abstract: An assembly for an aerial system includes a wing support foldably connected to a first and second side of a body of the aerial system, a protection structure coupled to the wing support and disposed over propellers coupled to the wing support, wherein at least one of the protection structure and the wing support includes at least one of a positioning hook and a positioning groove, wherein the protection structure and wing support are fixed relative to each other with the at least one of the positioning hook and the positioning groove.

Abstract: An unmanned aerial vehicle includes a fuselage body, a foldable wing assembly and a gear assembly. The foldable wing assembly, including a pair of opposing wing members, is coupled to the fuselage body and positionable in a stowed position and a deployed position. The gear assembly positions the wing members in a stowed position and a deployed position and include a support bracket assembly and a pair of opposing hinge members. The support bracket assembly is coupled to the fuselage body and including first and second support brackets forming a cavity therebetween and a pair of opposing hinge members. The pair of opposing hinge members are pivotably coupled to the support bracket assembly and positioned within the cavity. Each hinge member is coupled to a corresponding wing member and includes a set of gear teeth extending outwardly from an arcuate radially outer surface and coupled in a meshed arrangement.

Abstract: The invention provides antibody heavy chain constant regions with a hinge region modified to reduce binding to Fc? receptors. The modification occurs within positions 233-236 by replacement of natural residues by glycine(s) and/or deletion(s). Such modifications can reduce binding of an antibody bearing such a constant region to Fc? receptors to background levels. The constant regions can be incorporated into any format of antibody or Fc fusion protein. Such antibodies or fusion proteins can be used in methods of treatment, particularly those in which the mechanisms of action of the antibody or Fc fusion protein is not primarily or at all dependent on effector functions, as is the case when an antibody inhibits a receptor-ligand interaction or agonizes a receptor.

Abstract: Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) ligand (PD-L1) and inhibit PD-L1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD-L1-mediated functions.

Abstract: The present invention relates to the field of biomedical technology and discloses a cartridge and a testing device. The cartridge comprises a sample lysis compartment, a first sample mixing compartment and a first PCR compartment; a first valve is disposed between the sample lysis compartment and the first sample mixing compartment, the first valve controls the flowing or blocking of the sample between the sample lysis compartment and the first sample mixing compartment; a fourth valve is disposed between the first PCR compartment and the first sample mixing compartment, the fourth valve controls the flow or blocking of the sample between the first sample mixing compartment and the first PCR compartment; a first reagent is provided in the first sample mixing compartment. In the compartment, nucleic acids in the sample mix with the first reagent and is then sent to the first PCR compartment for amplification.

Abstract: A method for computation may include performing a first computation using a first system, wherein the first computation may be based, at least in part, on a first computation basis, performing a second computation using a second system, wherein the second computation may be based, at least in part, on a second computation basis, and coordinating the first computation and the second computation. The first computation basis may include a clock basis, and the second computation basis may include an event basis. The first computation may include a first operation, the second computation may include a second operation, and the coordinating the first computation and the second computation may include coordinating the first computation and the second computation based on the first operation and the second operation. The first operation may include an application computation operation, and the second operation may include a device computation operation.

Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.

Abstract: Provided is a sounding device, including frame and vibration system and magnetic circuit unit fixed to the frame. The vibration system includes diaphragm, voice coil driving the diaphragm to vibrate and sound, holder fixed to diaphragm, and auxiliary diaphragm spaced from diaphragm. The holder includes holder main body, first connection portion formed from holder main body to magnetic circuit unit and second connection portion spaced from first connection portion. The voice coil is fixed to second connection portion. One end of the auxiliary diaphragm is fixed to frame. One end of first connection portion away from holder main body bends and extends away from second connection portion to form flange. One end of auxiliary diaphragm away from frame is fixed to flange. The sounding device may reduce accuracy deviation and hidden dangers of gluing failure caused by rear assembling of the auxiliary diaphragm.

Abstract: The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided.

Abstract: A method for preparing a porous nano-fiber heterostructure photocatalytic filter screen includes: preparing a noble metal nanostructure with tunable spectra and a heterostructure composite photocatalyst of a photocatalytic material; and preparing a large area and multilayer porous nano-fiber filter screen structure, while utilizing a scattering enhancement effect of metal nanoparticles in an porous optical fiber to realize repeated conduction of sunlight in the optical fiber and finally interact with the composite photocatalyst on a surface to improve photocatalytic efficiency.

Abstract: The present disclosure provides a fire test system and method for tunnel structure based on real-time fusion of numerical and physical spaces. The fire test system includes: a physical test unit, to perform a holographic fire test on the typical segment components of tunnel structure system in a physical space, to obtain holographic characteristic parameter data of the typical components; a numerical analysis unit, to establish a full-scale numerical model of the tunnel-stratum composite system in a numerical space, to obtain multi-field coupling boundary data of the typical components; and a fusion control unit, to control and adjust a multi-field coupling boundary of the physical space according to the multi-field coupling boundary data, and to update and adjust an input parameter of the numerical space according to the holographic characteristic parameter data.

Abstract: An aerial system includes a body, a lift mechanism coupled to the body, a processing system, and at least one camera. The aerial system also includes a first motor configured to rotate the at least one camera about a first axis and a second motor configured to rotate the at least one camera about a second axis. The processing system is configured to determine a direction of travel of the aerial system and to cause the first motor and the second motor to automatically orient the at least one camera about the first axis and the second axis such that the at least one camera automatically faces the direction of travel of the aerial system.

Abstract: Provided are antibodies that specifically bind to TIGIT (T cell immunoreceptor with Ig and ITIM domains, WUCAM or Vstm3) and inhibit Tigit-mediated cellular signaling and activities in immune cells. The anti-TIGIT antibodies can be used to treat or diagnose cancer, infectious diseases or other pathological disorders that may be modulated by Tigit-mediated functions.

Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.

Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.

Abstract: Methods for enhancing the speed performance of solid-state storage devices using stream-aware garbage collection. A garbage collection method in according to an embodiment includes: searching, in each of a plurality of super-block groups G, for a super-block set C that satisfies: all of the super-blocks m within the super-block set C in the super-block group G contain a lesser amount of valid data than the other super-blocks within the super-block group G; and a total amount of valid data within the super-block set C are just enough to complete an entire super-block; selecting the super-block group G that includes the super-block set C with the maximum number of super-blocks m; and performing garbage collection on the super-block set C in the selected super-block group G.

Abstract: The present disclosure provides a diaphragm forming mold, including includes a mold body, the mold body includes forming regions and material removing regions connected with the forming regions, diaphragm bodies are formed in the forming regions, and at least one corrugated structure is formed in the material removing regions. The present disclosure may effectively improve a contraction effect of a material of diaphragm disposed in the material removing regions, thereby improving an overall contraction effect of the material of the diaphragm, reducing an amount of the compensation of the diaphragm forming mold for a size of the diaphragm, so that a flatness of the diaphragm after being molded is better.